Abstract
Great concern exists that athletes who regularly exercise are using dietary supplements and other purported ergogenic aids as a means for enhancing athletic performance and altering body composition.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Herbal treatments: the promises and pitfalls. Consum Rep. 1999;64:44–48.
Green GA, Uryasz FD, Petr TA, et al. NCAA study of substance use and abuse habits of college student-athletes. Clin J Sport Med. 2001;11:51–56.
IOC Press release. 4 April, 2002; http://www.olympic.or/uk/news/publications/press_ik.asp?release=266.
Deligiannis A, Bjöornstad H, Carre F, et al. ESC Study Group of Sports Cardiology. ESC Study Group of Sports Cardiology Position Paper on adverse cardiovascular effects of doping in athletes. Eur J Cardiovasc Prev Rehabil. 2006;13:687–694.
Melchert RB, Welder AA. Cardiovascular effects of androgenic-anabolic steroids. Med Sci Sports Exerc. 1995;27:1252–1262.
Kerr JM, Congeni JA. Anabolic-androgenic steroids: use and abuse in pediatric patients. Pediatr Clin N Am. 2007;54:771–785.
Sadler MA, Griffiths KA, McCredie RJ, et al. Androgenic anabolic steroids and arterial structure and function in male bodybuilders. J Am Coll Cardiol. 2001;37:224–230.
Hickson RC, Ball KL, Falduto MT. Adverse effects of anabolic steroids. Med Toxicol Adverse Drug Exp. 1989;4:254–271.
Glazer G. Arthogenic effects of anabolic steroids on serum lipid levels. Arch Intern Med. 1991;151:1925–1933.
Hartgens F, Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med. 2004;34:513–554.
National Institute on Drug Abuse Research Report – Steroid Abuse and Addiction. National Institutes of Health Education Publication No. 00–3721. Bethesda (MD): National Institutes of Health; 2000.
Hartgens F, Reitjens G, Keizer HA, et al. Effects of androgenic-anabolic steroids on apolipoprotiesn and lipoproteins (a). Br J Sports Med. 2004;38:253–259.
Sullivan ML, Martinez CM, Gennis P, et al. The cardiac toxicity of anabolic steroids. Prog Cardiovasc Dis. 1998;41:1–15.
Riebe D, Fernhall B, Thompson PD. The blood pressure response to exercise in anabolic steroid users. Med Sci Sports Exerc. 1992;24:633–637.
McKillop G, Todd IC, Ballantine D. Increased left ventricular mass in a bodybuilder using anabolic steroids. Br J Sports Med. 1986;20:151–152.
Urhausen A, Holpes R, Kindermann W. One and two-dimensional echocardiography in body builders using anabolic steroids. Eur J Appl Physiol. 1989;58:633–640.
Sullivan M, Martinez C, Gallagher J. Atrial fibrillation and anabolic steroids. J Emerg Med. 1999;17(5):851–857.
Urhausen A, Albers T, Kindermann W. Are the cardiac effects of anabolic steroid abuse in strength athletes reversible? Heart. 2004;90(5):496–501.
Clark BM, Schofield RS. Dilated cardiomyopathy and acute liver injury associated with combined use of ephedra, gamma-hydroxybutyrate, and anabolic steroids. Pharmacotherapy. 2005;25(5):756–761.
Cocaine and opiates found in Caminiti’s body. November 1, 2004, ESPN.com.
Corrigan B. DHEA and sport. Clin J Sport Med. 2002;12:236–241.
Holden C. Interest grows in anti-aging drug. Science. 1995;269:33.
Di Pasquale MG. Dehydroepitestosterone (DHEA). Drugs Sport. 1994;2:2–3.
Issajenko A. Running Risks. Macmillan, Canada. 1990:146.
Deyssig R. Frisch H. Blum WF, et al. Effect of growth hormone treatment on hormonal parameters, body composition and strength in athletes. Acta Endocrinol. 1993;128:313–318.
Bidlingmaier M, Wu Z, Strasburger CJ. Test method: GH. Bailliere’s Clin Endocrinol Metab. 2000;14:99–109.
Dean H. Does exogenous growth hormone improve athletic performance? Clin J Sport Med. 2002;12:250–253.
Rogol A. Sex steroid and growth hormone supplementation to enhance performance in adolescent athletes. Curr Opin Pediatr. 2000;12:382–387.
Colao A, Marzullo P, Di Somma C, et al. Growth hormone and the heart. Clin Endocrinol. 2001;54:137–154.
Audran M, Gareau R, Matecki S, et al. Effects of erythropoietin administration in training athletes and possible indirect detection in doping control. Med Sci Sport Exerc. 1999;31:639–645.
Vergouwen PC, Collee T, Marx JJ. Haematocrit in elite athletes. Int J Sports Med. 1999;20:538–541.
Noakes TD. Tainted glory. Doping and athletic performance. N Engl J Med. 2004;151:847–849.
World Anti-Doping Agency. The World Anti-Doping Code – The 2009 prohibited list, International Standard. Lausanne: WADA; 2008. Web site http://www.wada-ama.org.
George A. Central nervous system stimulants. Bailliere’s Clin Endocrinol Metab. 2000;14:79–88.
Cregler L. Substance abuse in sports: The impact of cocaine, alcohol, steroids, and other drugs on the heart. In: Williams RA, ed. The Athlete and Heart Disease: Diagnosis, Evaluation and Management. Philadelphia: Lippincott, Williams and Wilkins; 1999:131–153.
Billman GE. Cocaine: a review of its toxic actions on cardiac function. Crit Rev Toxicol. 1995;25:113–132.
Shekelle PG, Hardy ML, Morton SC, et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA. 2003;289:1537–1545.
Williams AD, Cribb PJ, Cooke MB, et al. The effect of ephedra and caffeine on maximal strength and power in resistance-trained athletes. J Strength Cond Res. 2008;22:464–470.
Malek MH, Housh TJ, Coburn JW, et al. Effects of eight weeks of caffeine supplementation and endurance training on aerobic fitness and body composition. J Strength Cond Res.2006;20(4):751–755.
Pipe A, Ayotte C. Nutritional supplements and doping. Clin J Sport Med. 2002;12:245–249.
Clauson KA, Shields KM, McQueen CE, et al. Safety issues associated with commercially available energy drinks. J Am Pharm Assoc. 2008;48(3):e55–e63.
Graham TE, Spriet LL. Caffeine and exercise performance. Sport Sci Exerc. 1996;9:1.
Australia New Zealand Food Authority. Report of the expert group on the safety aspects of dietary caffeine ANZFA, Canberra. 2000.
Ellison RC, Singer MR, Moore LL. Current caffeine intake of young children; amount and sources. J Am Diet Assoc. 1995;95:802–803.
Morgan KJ, Stults VJ, Zabik ME. Amount and dietary sources of caffeine and saccharin intake by individuals 5–18 years. Regul Toxiol Pharmacol. 1982;2:296–307.
Nawrot P, Jorden S, Eastwood J, Rostein J, Hugenholtz A, Feeley M. Effects of caffeine on human health Food Addit Contam 2003;20:1–30.
Frary CD, Johnson RK, Wang MQ. Food sources and intakes of caffeine in the diets of persons in the United States. J Am Diet Assoc. 2003;103:1326–1331.
Santa Maria A, Lopez A, Diaz M, et al. Evaluation of toxicity of guarana with invitro bioassays. Ecotoxicol Environ Saf. 1998;39:164–167.
Suggested Web sites
American College of Cardiology – http://www.acc.org
American College of Sports Medicine – http://www.acsm.org
National Collegiate Athletic Association – http://www.ncaa.org
United States Anti-Doping Agency – http://www.usada.org
World Anti-Doping Agency – http://www.wada-ama.org
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Benjamin, H.J., Congeni, J.A. (2011). Cardiac Effects of Ergogenic Aides and Supplements. In: Lawless, C. (eds) Sports Cardiology Essentials. Springer, New York, NY. https://doi.org/10.1007/978-0-387-92775-6_20
Download citation
DOI: https://doi.org/10.1007/978-0-387-92775-6_20
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-92774-9
Online ISBN: 978-0-387-92775-6
eBook Packages: MedicineMedicine (R0)